tbuckley/cabot-search huggingface dataset:
Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer
Authors: Susana Campos, Oday Hamid, Michael V. Seiden, Amit Oza, Marie Plante, Ronald K. Potkul, Peter F. Lenehan, Eric P. Kaldjian, Mary L. Varterasian, Cheryl Jordan, Claudie Charbonneau, Hal Hirte
Journal: Journal of Clinical Oncology (2005)

To evaluate the antitumor activity and toxicity of two doses of CI-1033 in patients with platinum-refractory or recurrent ovarian cancer, and to determine baseline expression of epidermal growth factor receptor in tumor cells.This phase II, open-label clinical trial evaluated CI-1033 in patients with ovarian cancer who failed prior platinum-based therapy. Two oral doses of CI-1033 were evaluated--a 50-mg and a 200--mg oral dose administered daily for 21 days in a 28-day cycle. Patients were evaluated for tumor response and toxicity; in addition, archival baseline tumor samples were analyzed by immunohistochemistry for erbB1 to erbB4 status.One hundred five eligible patients were treated. Baseline demographic characteristics were balanced in this heavily pretreated patient population. The median number of prior chemotherapy regimens received was four. The most commonly encountered drug-related adverse events for both dose arms were gastrointestinal (diarrhea, nausea, stomatitis) toxicity, asthenia, and rash. No responses were observed. Stable disease was confirmed in 34% and 26% of patients in the 200-mg and 50-mg arms, respectively, and 1-year survival rates were 38.5% and 37.7%, respectively. Baseline erbB3 and erbB4 revealed the highest frequencies of expression, while erbB2 was the lowest.CI-1033 did not show activity in unscreened patients with advanced ovarian cancer. At 50 mg/d, CI-1033 had a more favorable adverse events profile than at 200 mg/d. erbB3 and erbB4 receptors showed the highest expression in tumor samples while erbB2 revealed the least. There appears to be no association between baseline erbB expression and disease stability.
Interferon alfa-2b in mixed cryoglobulinaemia: a controlled crossover trial.
Authors: C Ferri, E Marzo, G Longombardo, L La Civita, F Lombardini, D Giuggioli, R Vanacore, A M Liberati, A Mazzoni, F Greco
Journal: Gut (1993)

To confirm the positive results of a preliminary trial, 26 patients with mixed cryoglobulinaemia were enrolled in a controlled, randomised, crossover trial with interferon alfa-2b. A significant improvement was seen in the purpura score and alanine aminotransferase activities during six months9 treatment, and was associated with a significant decrease in cryocrit and a returning to normal of the lymphocyte CD4/CD8 ratio (in eight of nine patients). No significant variations were seen during the six month period without interferon. Only six patients withdrew from treatment, three because of side effects and three because of poor compliance.
The Transient Receptor Potential Superfamily of Ion Channels
Authors: Chou-Long Huang
Journal: Journal of the American Society of Nephrology (2004)

ABSTRACT. The transient receptor potential (TRP) superfamily of proteins is cation-selective ion channels with six predicted transmembrane segments and intracellularly localized amino and carboxyl termini. Members of the TRP superfamily are identified on the basis of amino acid sequence and structural similarity and are classified into TRPC, TRPV, TRPM, TRPP, TRPN, and TRPML subfamilies. TRP channels are widespread and have diverse functions, ranging from thermal, tactile, taste, osmolar, and fluid flow sensing to transepithelial Ca2+ and Mg2+ transport. Mutations of TRP proteins produce many renal diseases, including Mg2+ wasting, hypocalcemia, and polycystic kidney diseases. This review focuses on recent advances in the understanding of their functions.
Single‐episode photodynamic therapy and vulval intraepithelial neoplasia type III resistant to conventional therapy
Authors: H.A. Kurwa, R.J. Barlow, S. Neill
Journal: British Journal of Dermatology (2000)

Journal Article Single‐episode photodynamic therapy and vulval intraepithelial neoplasia type III resistant to conventional therapy Get access H.A. Kurwa, H.A. Kurwa Dermatological Surgery and Laser Unit and Search for other works by this author on: Oxford Academic Google Scholar R.J. Barlow, R.J. Barlow Dermatological Surgery and Laser Unit and Search for other works by this author on: Oxford Academic Google Scholar S. Neill S. Neill Vulval Clinic, St John's Institute of Dermatology, St Thomas' Hospital, London SE1 7EH, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 143, Issue 5, 1 November 2000, Pages 1040–1042, https://doi.org/10.1046/j.1365-2133.2000.03785.x Published: 01 November 2000
Services Available for Total Joint Replacement
Authors: R. T. Austin
Journal: BMJ (1975)

and were accordingly thought to have M.S., four had results between 45-4 and 47-7% and were thought to have other neurological disease (O.N.D.), while the last patient gave a 508°,' result-that is, in the normal range-and her transient disability was thought to be a toxic manifestation of oral contraceptives.Since the relationship of Devic's disease (neuromyeli,tis optica) has long been the subject of debate we studied two clear cases of this condition and both gave results in the O.N.D. range.Your article (like that which appeared in the Lancet3) dwells on the association between measles and M.S. but passes over recent work in relation to other viruses, in particular the finding of high vaccinia anti- body levels in the spinal fluid in M.S.4-6 Nor does it make reference to the extensive re- searches of Daniel,7 who was able to demon- strate a striking association of antibodies against several viruses in M.S. but found no grounds for associating it specifically with measles.A-We are, etc.,
SERUM CHOLESTEROL, URIC ACID AND PROTEINS IN PSORIASIS.
Authors: A. TICKNER, P. D. MIER
Journal: British Journal of Dermatology (1960)

Journal Article SERUM CHOLESTEROL, URIC ACID AND PROTEINS IN PSORIASIS. Get access A. TICKNER, A. TICKNER Institute of Dermatology, St. John's Hospital for Diseases of the Skin, Homerton Grove, London, E.9 Search for other works by this author on: Oxford Academic Google Scholar P. D. MIER P. D. MIER Institute of Dermatology, St. John's Hospital for Diseases of the Skin, Homerton Grove, London, E.9 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 72, Issue 4, 1 April 1960, Pages 131–137, https://doi.org/10.1111/j.1365-2133.1960.tb13860.x Published: 01 April 1960
Winners of Anti-Tobacco Contest See D.C.
Authors: P. A. Newman
Journal: JNCI Journal of the National Cancer Institute (1990)

Journal Article Winners of Anti-Tobacco Contest See D.C. Get access Patricia A. Newman Patricia A. Newman Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 21, 7 November 1990, Page 1671, https://doi.org/10.1093/jnci/82.21.1671 Published: 07 November 1990
Is there a microangiopathic antiphospholipid syndrome?
Authors: R. A Asherson, S. S Pierangeli, R. Cervera
Journal: Annals of the Rheumatic Diseases (2006)

Revealing the evolution of the term APS and its commonalities with other microangiopathic disorders

The occurrence of small-vessel occlusions (thrombotic microangiopathy) in association with anti-phospholipid antibodies (aPL) affecting, for example, the retinal vessels,1 the nail fold,2,3 the skin,4 or major intrabdominal organs such as the kidney, the liver or the bowel,5 although uncommon, is well documented. These occlusions have been described in the simple or classic antiphospholipid syndrome (APS), whether or not associated with systemic lupus erythematosus (SLE), or in the primary APS,6 but they do not in any way dominate the clinical picture in these conditions. However, with the description and definition of the catastrophic APS (also known as Asherson’s syndrome) in 19927,8 (a new subset of the APS, often fatal, with many distinguishing characteristics separating it from the simple APS),9–11 there has been renewed interest in the thrombotic microangiopathies and their association with aPL. Although large-vessel occlusions do occur in catastrophic APS, they do not dominate the clinical picture, and their frequency is completely different from that encountered in the classic APS itself. Additionally, the catastrophic APS is frequently accompanied by a systemic inflammatory response syndrome (SIRS).

The term thrombotic microangiopathic haemolytic anaemia (TMHA) was originally introduced by Symmers12 in 1952 to describe a clinical state with localised or diffuse microvascular thrombosis in association with haemolytic anaemia and fragmented red cells referred to as schistocytes. Indeed, the great haematologist John Dacie and his colleagues13 published a seminal paper on TMHA and related the condition to vascular damage some 10 years later. TMHA encompasses a spectrum of disorders including thrombotic thrombocytopenic purpura (TTP), haemolytic–uraemic syndrome (HUS), malignant hypertension, postpartum renal failure, pre-eclampsia and catastrophic APS. Recent articles still refer to the difficulty in distinguishing among these conditions …
Endoscopy and gastric cancer.
Authors: G Holdstock, S Bruce
Journal: Gut (1981)

In an attempt to assess the impact of upper gastrointestinal endoscopy on the outcome of patients with gastric cancer, we have studied 483 patients with gastric cancer from three centres with differing endoscopic practice. The introduction of an open access general practitioners endoscopy service led to a 10-fold increase in the number of endoscopies being performed per head of population, but there was no demonstrable effect on prognosis or on the duration of symptoms before diagnosis. There was no increase in the proportion of early gastric cancer diagnosed.
Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy
Authors: Juan Zhao, Ji-Yuan Zhang, Hong-Wei Yu, Yu-Lan He, Jing-Jing Zhao, Juan Li, Yue-Ke Zhu, Qin-Wei Yao, Jin-Huan Wang, Hai-Xia Liu, Shu-Yun Shi, Zheng-Sheng Zou, Xiang-Sheng Xu, Chun-Bao Zhou, Fu-Sheng Wang, Qing-Hua Meng
Journal: Cellular and Molecular Immunology (2012)
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Authors: Susan L. Cohn, Andrew D.J. Pearson, Wendy B. London, Tom Monclair, Peter F. Ambros, Garrett M. Brodeur, Andreas Faldum, Barbara Hero, Tomoko Iehara, David Machin, Veronique Mosseri, Thorsten Simon, Alberto Garaventa, Victoria Castel, Katherine K. Matthay
Journal: Journal of Clinical Oncology (2008)

Because current approaches to risk classification and treatment stratification for children with neuroblastoma (NB) vary greatly throughout the world, it is difficult to directly compare risk-based clinical trials. The International Neuroblastoma Risk Group (INRG) classification system was developed to establish a consensus approach for pretreatment risk stratification.The statistical and clinical significance of 13 potential prognostic factors were analyzed in a cohort of 8,800 children diagnosed with NB between 1990 and 2002 from North America and Australia (Children's Oncology Group), Europe (International Society of Pediatric Oncology Europe Neuroblastoma Group and German Pediatric Oncology and Hematology Group), and Japan. Survival tree regression analyses using event-free survival (EFS) as the primary end point were performed to test the prognostic significance of the 13 factors.Stage, age, histologic category, grade of tumor differentiation, the status of the MYCN oncogene, chromosome 11q status, and DNA ploidy were the most highly statistically significant and clinically relevant factors. A new staging system (INRG Staging System) based on clinical criteria and tumor imaging was developed for the INRG Classification System. The optimal age cutoff was determined to be between 15 and 19 months, and 18 months was selected for the classification system. Sixteen pretreatment groups were defined on the basis of clinical criteria and statistically significantly different EFS of the cohort stratified by the INRG criteria. Patients with 5-year EFS more than 85%, more than 75% to < or = 85%, > or = 50% to < or = 75%, or less than 50% were classified as very low risk, low risk, intermediate risk, or high risk, respectively.By defining homogenous pretreatment patient cohorts, the INRG classification system will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world and the development of international collaborative studies.
Associations between Human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study
Authors: E W Karlson, L B Chibnik, J Cui, R M Plenge, R J Glass, N E Maher, A Parker, R Roubenoff, E Izmailova, J S Coblyn, M E Weinblatt, N A Shadick
Journal: Annals of the Rheumatic Diseases (2007)

HLA-DRB1 shared epitope (HLA-SE), PTPN22 and CTLA4 alleles are associated with cyclic citrullinated peptide (CCP) and rheumatoid arthritis (RA).We examined associations between HLA-SE, PTPN22, CTLA4 genotypes and RA phenotypes in a large cohort to (a) replicate prior associations with CCP status, and (b) determine associations with radiographic erosions and age of diagnosis.A total of 689 RA patients from the Brigham RA Sequential Study (BRASS) were genotyped for HLA-SE, PTPN22 (rs2476601) and CTLA4 (rs3087243). Association between genotypes and CCP, rheumatoid factor (RF) erosive phenotypes and age at diagnosis were assessed with multivariable models adjusting for age, sex and disease duration. Novel causal pathway analysis was used to test the hypothesis that genetic risk factors and CCP are in the causal pathway for predicting erosions.In multivariable analysis, presence of any HLA-SE was strongly associated with CCP+ (odds ratio (OR) 3.05, 95% CI 2.18-4.25), and RF+ (OR 2.53, 95% CI 1.83-3.5) phenotypes; presence of any PTPN22 T allele was associated with CCP+ (OR 1.81, 95% CI 1.24-2.66) and RF+ phenotypes (OR 1.84, 95% CI 1.27-2.66). CTLA4 was not associated with CCP or RF phenotypes. While HLA-SE was associated with erosive RA phenotype (OR 1.52, 95% CI 1.01-2.17), this was no longer significant after conditioning on CCP. PTPN22 and CTLA4 were not associated with erosive phenotype. Presence of any HLA-SE was associated with an average 3.6 years earlier diagnosis compared with absence of HLA-SE (41.3 vs 44.9 years, p = 0.002) and PTPN22 was associated with a 4.2 years earlier age of diagnosis (39.5 vs 43.6 years, p = 0.002). CTLA4 genotypes were not associated with age at diagnosis of RA.In this large clinical cohort, we replicated the association between HLA-SE and PTPN22, but not CTLA4 with CCP+ and RF+ phenotypes. We also found evidence for associations between HLA-SE, and PTPN22 and earlier age at diagnosis. Since HLA-SE is associated with erosive phenotype in unconditional analysis, but is not significant after conditioning on CCP, this suggests that CCP is in the causal pathway for predicting erosive phenotype.
Prognostic laboratory markers of joint damage in rheumatoid arthritis
Authors: E Lindqvist
Journal: Annals of the Rheumatic Diseases (2004)

<b>Objective:</b> To investigate whether determination of a set of laboratory markers at baseline provides prognostic information on joint damage in hands and feet in rheumatoid arthritis. <b>Methods:</b> 183 patients with early rheumatoid arthritis included in a prospective study were examined. Radiographic changes in hands and feet at 5 and 10 years after inclusion were evaluated (Larsen). The markers analysed were: erythrocyte sedimentation rate (ESR); HLA-DRB alleles typed by restriction fragment length polymorphism; and C reactive protein, cartilage oligomeric matrix protein (COMP), rheumatoid factor (RF) (IgG, IgA, and IgM subtypes), antibodies against cyclic citrullinated peptide (anti-CCP), and antibodies against interleukin 1α (anti-IL1α), analysed by immunoassays. Multiple linear regression with backward elimination was used to determine the prognostic value of the variables. <b>Results:</b> 117/176 patients were positive for IgG RF, 138/176 for IgA RF, 139/176 for IgM RF, 140/176 for anti-CCP, and 40/182 for anti-IL1α. After five years, ESR, the presence of IgA RF, serum COMP, and the presence of anti-CCP were significantly associated with more severe joint damage, and the presence of anti-IL1α with less severe joint damage. Baseline C reactive protein and anti-CCP predicted radiographic outcome after 10 years. A stronger prediction was obtained by combining the prognostic factors. <b>Conclusions:</b> Early determination of anti-CCP, IgA RF, anti-IL-1α, ESR, C reactive protein, and COMP predicted the development of joint damage in hands and feet in this cohort. A combination of these measures reflecting different aspects of the disease process should be useful for evaluating prognosis in individual patients with early rheumatoid arthritis.
Does Erythropoietin Promote Tumor Growth?
Authors: Donghoon Yoon, Neeraj Agarwal, Josef T. Prchal
Journal: Clinical Cancer Research (2008)

To the Editors: In the August 15, 2007 issue of Clinical Cancer Research , Saintigny et al. reported the expression of erythropoietin (Epo) and Epo receptor (EpoR) in stage I non–small cell lung cancer ([1][1]). They showed that Epo/EpoR coexpression is associated with poor survival in stage I non
The effect of terfenadine on dermographic wealing
Authors: L. B. KRAUSE, SAM SHUSTER
Journal: British Journal of Dermatology (1984)

Journal Article The effect of terfenadine on dermographic wealing Get access L. B. KRAUSE, L. B. KRAUSE University Department of Dermatology, Newcastle upon Tyne Search for other works by this author on: Oxford Academic Google Scholar SAM SHUSTER SAM SHUSTER University Department of Dermatology, Newcastle upon Tyne Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 110, Issue 1, 1 January 1984, Pages 73–79, https://doi.org/10.1111/j.1365-2133.1984.tb07315.x Published: 01 January 1984 Article history Accepted: 15 July 1983 Published: 01 January 1984
Relationship between cholinergic airway tone and serum immunoglobulin E in human subjects
Authors: N Endoh, M Ichinose, T Takahashi, M Miura, N Kageyama, Y Mashito, H Sugiura, K Ikeda, T Takasaka, K Shirato
Journal: European Respiratory Journal (1998)

It has recently been shown that immunoglobulin (Ig)E facilitates the cholinergic bronchoconstrictor pathway in human tissue in vitro. However, whether this occurs in humans in vivo has not been clarified. In this study, the bronchodilator responses were examined to inhalation of a submaximal dose of the anticholinergic agent oxitropium bromide (600 microg) in normal and allergic subjects with various levels of total serum IgE. Values of the forced expiratory volume in one second (FEV1) for all subjects were greater than 80% of predicted, but were negatively correlated with serum IgE levels (p&lt;0.01). Oxitropium bromide inhalation induced an increase in FEV1 that was significantly greater in allergic rhinitis patients with high serum IgE (155+/-20 mL (mean+/-SEM), p&lt;0.05) than in healthy subjects (64+/-21 mL) or those with allergic rhinitis but low serum IgE (82+/-21 mL, p&lt;0.05). In contrast, the effects of the inhaled beta2-adrenergic agent orciprenaline sulphate (2.25 mg) were not significantly different among the three groups. In conclusion, higher serum immunoglobulin E levels were correlated with lower values of the forced expiratory volume in one second, and anticholinergic agents, but not beta2-adrenergic agents, caused more pronounced bronchodilation in subjects with high than in those with low immunoglobulin E levels. These data suggest that serum immunoglobulin E may be one of the factors that determine the airway tone, possibly via cholinergic mechanisms.
Estrogen Increases Bone Marrow–Derived Endothelial Progenitor Cell Production and Diminishes Neointima Formation
Authors: Kerstin Strehlow, Nikos Werner, Jan Berweiler, Andreas Link, Ulrich Dirnagl, Josef Priller, Kerstin Laufs, Leyli Ghaeni, Milan Milosevic, Michael Böhm, Georg Nickenig
Journal: Circulation (2003)

Background— Estrogens improve endothelial function and accelerate reendothelialization after vascular injury via largely unknown mechanisms. Bone marrow–derived endothelial progenitor cells (EPCs) are thought to positively influence endothelialization, vascular repair, and angiogenesis. Methods and Results— In mice subjected to sham operation, ovariectomy, or ovariectomy and estrogen replacement treatment, estrogen deficiency significantly decreased EPCs circulating in the peripheral blood and residing in the bone marrow, as well as EPCs that were in vitro expanded from spleen-derived mononuclear cells. These effects were completely prevented by estrogen replacement. Human women with increased estrogen plasma concentrations also displayed profoundly increased levels of circulating EPCs. Estrogens increase EPC numbers through a decreased apoptosis rate, which is mediated via a caspase-8–dependent pathway. Estrogen deficiency increased neointima formation after carotid artery injury in mice, but this effect was diminished by estrogen replacement therapy. In mice transplanted with green fluorescent protein–positive bone marrow, reendothelialization of injured vessel segments by bone marrow–derived cells was decreased during estrogen deficiency and increased in response to estrogen treatment. Conclusions— Estrogens increase numbers of EPCs by antiapoptotic effects leading to accelerated vascular repair and decreased neointima formation.
Requirement for three signals in B cell responses. II. Analysis of antigen- and Ia-restricted T helper cell-B cell interaction.
Authors: R H Zubler, O Kanagawa
Journal: The Journal of Experimental Medicine (1982)

We have recently reported that resting B cells must receive at least three different signals in a T helper cell (TH)-dependent as well as in a lipopolysaccharide (LPS)-induced B cell response (3), i.e., a specific TH signal (that can be bypassed by LPS), a nonspecific TH signal (mediated by Ia or antigen-nonspecific B cell helper factor), and an antigen (hapten) signal. In a system using male (H-Y) antigen-specific cloned TH of C57BL/6 origin and male (or female) B cells, we now confirm and extend these findings by demonstrating that H-Y-specific TH must see both H-Y and Ia determinants on the B cells (and not only on macrophages) to provide the first specific TH signal required for a plaque-forming cell (PFC) response. This signal was interfered with by a monoclonal anti-I-Ab antibody at the B cell level, was not mediated by detectable soluble factors (in contrast to the nonspecific signal also provided by the TH), and could be bypassed by LPS, in which case anti-I-Ab antibody had no effect. However, although the H-Y-specific TH induced a polyclonal PFC response (B cell differentiation) in the apparent absence of an antigen seen by the B cells, significant clonal expansion of PFC precursors occurred only when the B cells also recognized an antigen (hapten).